Business Wire

Janssen Reports Top-Line Phase 3 Results for TREMFYA® (guselkumab) in Adults with Active Psoriatic Arthritis

Share

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis (PsA). Both studies met their primary endpoints of American College of Rheumatology 20% improvement (ACR20), and the safety profiles observed for guselkumab in the DISCOVER programme were consistent with previous studies of guselkumab and current prescribing information.1

The DISCOVER programme comprises the first-ever Phase 3 studies evaluating an IL-23 p19 inhibitor for the treatment of psoriatic arthritis, and data will be presented at upcoming scientific medical meetings. Data from the two DISCOVER studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of guselkumab as a treatment for psoriatic arthritis, which are anticipated for later this year.

The DISCOVER programme consists of DISCOVER-1 and DISCOVER-2, two randomised, double-blind, multicentre Phase 3 studies designed to evaluate efficacy and safety of subcutaneous guselkumab in patients with active PsA compared to placebo. In addition to the primary endpoint of ACR20 response at week 24, multiple secondary endpoints were assessed that included ACR50/70, resolution of soft tissue inflammation (enthesitis and dactylitis), disease activity (DAS-28 CRP), improvement in physical function (HAQ-DI), skin clearance (IGA), and quality of life (SF-36 PCS and MCS). DISCOVER-2 also assessed effect on structural damage (vdH-S) as a key secondary endpoint.1

DISCOVER-1 included 381 participants, including participants previously treated with biologic anti-TNF biologics. The study continues through 52 weeks. DISCOVER-2 included 739 bio-naive participants and continues through 100 weeks.

#ENDS#

About Psoriatic Arthritis (PsA)

PsA is a chronic, immune-mediated inflammatory disease characterised by both joint inflammation and the skin lesions associated with psoriasis.2 It is estimated that one third of the 125 million people who are living with psoriasis worldwide will also develop PsA.3 The disease causes pain, stiffness and swelling in and around the joints and commonly appears between the ages of 30 and 50, but can develop at any time.2 Though the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in the onset of the disease.2

About guselkumab 4

On 10 November 2017, TREMFYA® (guselkumab) was granted market authorisation in the European Union (EU) for the treatment of adult patients with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy).4

Guselkumab is the first psoriasis treatment licensed in the EU to selectively target IL-23, a key driver of the immune inflammatory response in psoriasis.5,6,7,8 Guselkumab is a subcutaneous, self-injectable treatment for psoriasis (following training). Treatment requires two starter doses, one initially and the other four weeks later, followed by a maintenance dose once every eight weeks (q8w) thereafter.5,6,9

Ongoing trials include: two Phase 3 programmes evaluating guselkumab in the treatment of active PsA and a Phase 2b programmes in Crohn’s disease, and two Phase 2 programmes – one for the treatment of ulcerative colitis and the other for the treatment of hidradenitis suppurativa.

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to TREMFYA® which is currently approved in the US, Canada and the EU.

Prescribing and safety information

For complete EU prescribing and safety information, please visit: https://www.medicines.org.uk/emc/medicine/34321

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/EMEA. Follow us at www.twitter.com/JanssenEMEA.

Janssen-Cilag International NV, the marketing authorisation holder for TREMFYA® in the EU, and Janssen Research & Development, LLC, are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding new study data on guselkumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV and Janssen Research & Development, LLC. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended 30 December, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

# # #

1 Janssen Pharmaceutical Companies of Johnson & Johnson. Data on file (2019).

2 Mayo Clinic. Psoriatic Arthritis. http://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/home/ovc-20233896 . Accessed June 2019.

3 International Federation of Psoriasis Associations. Our Cause: Psoriasis. Available at: https://ifpa-pso.com/our-cause/. Accessed June 2019.

4 European Medicines Agency. Tremfya 100mg solution for injection. 2017. Available at: https://www.medicines.org.uk/emc/medicine/34321. Accessed June 2019.

5 Blauvelt A, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017;76(3):405–17.

6 Reich K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017;76(3):418–31.

7 Langley R, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018;178(1):114–23.

8 Bachelez, H. Interleukin 23 inhibitors for psoriasis: not just another number. The Lancet 2017;390(10091):208–10.

9 ClinicalTrials.gov. A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE). Identifier NCT03090100. Available at: https://clinicaltrials.gov/ct2/show/NCT03090100. Accessed June 2019.

Contact information

Media Contact:
Emily Bone
Phone: +44 787-639-4360
ebone1@its.jnj.com

Investor Relations:
Christopher DelOrefice
Phone: +1 732-524-2955

Lesley Fishman
Phone: +1 732-524-3922

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CDIB Capital Group Appoints Mr. Angelo J.Y. Koo as Chairman to Lead Global Asset Management Business18.10.2019 11:35:00 CESTPress release

China Development Financial (“CDF”, TWSE: 2883) announced in 2H19 investor conference that its subsidiary CDIB Capital Group (“CDIB”) has achieved NT$41.1bn in AUM of its private equity funds at end-September, successfully transforming its proprietary investment business into an asset management model. Recently, the CDIB Board has appointed Mr. Angelo J.Y. Koo as Chairman to lead CDIB towards a global asset management brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191018005231/en/ Mr. Angelo J.Y. Koo (fourth from the right in the back row) is the Chairman of the CDIB Education and Cultural Affairs Foundation. (Photo: Business Wire) CDIB has been focused on expanding global investment portfolio, the newly launched “CDIB Intelligence Partners Fund” as an example. On a projected scale of up to US$75mn, the fund is actively seeking institutional investors in telecom, retail, technology and financial service sectors, targe

Concept Medical is Granted CE Certification for Their Sirolimus Coated MagicTouch Group of Products18.10.2019 11:25:00 CESTPress release

The CE certified products/brands are as listed below: MagicTouch – PTA (Sirolimus Coated PTA Balloon Catheter) for peripheral arterial disease MagicTouch – ED (Sirolimus Coated Balloon Catheter) for Erectile Dysfunction MagicTouch – AVF (Sirolimus Coated PTA Balloon Catheter) for Arterio-Venous Fistula and Graft MagicTouch – PTA is the only commercially available and CE certified Sirolimus coated balloon catheter for peripheral arterial diseases. Percutaneous transluminal angioplasty (PTA) is a procedure that can open a blocked blood vessel using a small catheter with a "balloon" at one end. The currently accepted procedure is to use drug delivery devices to deliver drugs that inhibit the inflammatory and proliferative pathways that lead to restenosis. Sirolimus is widely accepted as a drug of choice for such a purpose. Several studies have demonstrated that Erectile Dysfunction (ED) is increasingly prevalent with age. Approximately 40% of men are affected by the age of 40 years and ne

Schlumberger Announces Third-Quarter 2019 Results18.10.2019 10:50:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2019 Jun. 30, 2019 Sept. 30, 2018 Sequential Year-on-year Revenue $8,541 $8,269 $8,504 3% 0% Income (loss) before taxes - GAAP basis $(11,971) $593 $787 n/m n/m Pretax segment operating income* $1,096 $968 $1,152 13% -5% Pretax segment operating margin* 12.8% 11.7% 13.5% 113 bps -71 bps Net income (loss) - GAAP basis $(11,383) $492 $644 n/m n/m Net income, excluding charges & credits* $596 $492 $644 21% -7% Diluted EPS (loss per share) - GAAP basis $(8.22) $0.35 $0.46 n/m n/m Diluted EPS, excluding charges & credits* $0.43 $0.35 $0.46 23% -7% North America revenue $2,850 $2,801 $3,189 2% -11% International revenue $5,629 $5,463 $5,215 3% 8% North America revenue, excluding Cameron $2,261 $2,201 $2,545 3% -11% International revenue, excluding Cameron $4,857 $4,708 $4,502 3% 8% *These are non-GAAP financial measures. See

Denodo Announces DataFest 2019 in London: Third Annual Conference in Europe for Data Professionals Provides Valuable Insights on Machine Learning, Cloud and Advanced Analytics18.10.2019 06:15:00 CESTPress release

Denodo, the leader in data virtualization, announced its 3rd annual user conference in Europe, Denodo DataFest, on 23rd October in London. In this conference, attendees will learn strategies on how to leverage data virtualization to enable highly flexible, agile, and powerful BI architectures that are paving the way to multi-cloud adoption. The event can be attended in person or online by connecting to the live stream. “I am looking forward to speaking at the Denodo DataFest 2019 user conference and am excited to share how we are using data virtualization to enable self-service BI for business users at Festo,” said Diethard Frank, IT Product Manager, Big Data & AI Services at Festo. “I’m excited to share our experience and lessons learned that will hopefully help other organizations think about how to leverage modern technology approaches to truly innovate and uncover hidden value from their data.” Through this immersive conference, Denodo is bringing together visionary leaders and tec

STALICLA Appoints Stéphane Baudouin as Chief of Science17.10.2019 22:01:00 CESTPress release

STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant Research Scientist at Greenwood Genetic Center (SC, USA). STALICLA will pursue its collaboration with the Greenwood Genetic Center, which is a leading translational research center in genetics and neurodevelopmental disorders, including ASD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005803/en/ STALICLA's Chief of Science - Stéphane Baudouin (Photo: STALICLA) Dr. Baudouin is a neurobiologist with extensive research experience in the pathophysiology of Autism Spectrum Disorder. His previous work focused on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions. Before joining STALICLA, Stéphane was a Senior

Laser System Partnership Sets Sights on Ending Toll Road Delays17.10.2019 22:00:00 CESTPress release

A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics. Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions. Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.